Dr. Agarwal on the Progression of the COSMIC-021 Trial in mCRPC

Video

Neeraj Agarwal, MD, discusses the rationale for the expansion of cohort 6 in the COSMIC-021 trial in metastatic castration-resistant prostate cancer.

Neeraj Agarwal, MD, professor of medicine, and director of the Genitourinary Oncology Program, Huntsman Cancer Institute, discusses the rationale for the expansion of cohort 6 in the COSMIC-021 trial in metastatic castration-resistant prostate cancer (mCRPC).

The multicenter, open-label, phase 1b trial tested the combination of cabozantinib (Cabometyx) and atezolizumab (Tecentriq) in a wide variety of patient populations, says Agarwal. Based on encouraging efficacy and safety data, cohort 6, which consisted of patients with mCRPC, was expanded to a total of 130 patients. At this point, a large phase 3 trial had been planned.

The phase 3 trial will accrue patients all over the globe, including the United States. This study will further evaluate the combination of cabozantinib and atezolizumab in patients mCRPC, Agarwal concludes.

Related Videos
Jeffrey Zonder, MD
Jun Gong, MD
John Michael Bryant, MD,
Chandler H. Park, MD, FACP
Kathryn Beckermann, MD, PhD
Eleonora Dondossola, PhD
William B. Pearse, MD
Pasi A. Jänne, MD, PhD, director, Lowe Center for Thoracic Oncology, director, Belfer Center for Applied Cancer Science, director, Chen-Huang Center for EGFR Mutant Lung Cancers, senior physician, David M. Livingston, MD, Chair, Dana-Farber Cancer Institute; professor, medicine, Harvard Medical School
Rachid Baz, MD, section head, Myeloma, Department of Malignant Hematology, Moffitt Cancer Center; co-director, Pentecost Family Myeloma Research Center
Harriet Kluger, MD, Harvey and Kate Cushing Professor of Medicine (Oncology) and of Dermatology; director, Yale SPORE in Skin Cancer; vice chair, Translational Research, Internal Medicine; chief, Division of Skin and Kidney Cancer; associate cancer center director, Education, Training and Faculty Development; deputy section chief, Medical Oncology, Yale Cancer Center